Nothing is going right for Amgen these days. Amgen and partner company UCB announced late-stage trial results for its experimental osteoporosis treatment, Evenity, on Sunday. While the drug worked, Amgen noted a higher incidence of heart-related side effects than previously expected. Amgen now says the drug is unlikely to win approval from the Food and Drug Administration this year. Investors had been expecting an FDA decision by...

Source: Wall Street Journal May 22, 2017 16:52 UTC